The U.S. Food and Drug Administration (FDA) announced a revision to the boxed warning on the label for FABHALTA (Iptacopan) on 2026-07-16. This significant update highlights an increased risk of serious infections, specifically those caused by encapsulated bacteria, for patients taking this complement inhibitor.
Background
FABHALTA (Iptacopan) is a complement inhibitor. Complement inhibitors, by their mechanism of action, can modulate the immune system, which may lead to an altered susceptibility to certain types of infections. The revised boxed warning specifically addresses the risk of serious infections, particularly those caused by encapsulated bacteria, including Streptococcus pneumoniae and Neisseria meningitidis. These types of bacteria are known to cause severe diseases such as meningitis, sepsis, and pneumonia.
What this means
The updated boxed warning for FABHALTA serves as a critical alert for healthcare professionals and patients regarding the potential for severe infections. Clinicians prescribing Iptacopan should be acutely aware of this heightened risk, especially concerning encapsulated bacteria, and consider appropriate prophylactic measures, such as vaccination, or enhanced monitoring strategies for signs of infection. This revision underscores the importance of thorough patient education on recognizing infection symptoms and the necessity of seeking prompt medical attention. Patients should be advised to report any signs of infection immediately to their healthcare provider. The FDA's action emphasizes the ongoing commitment to patient safety and the continuous evaluation of drug profiles post-market.
Source
This information was sourced from the FDA, documenting a label revision for FABHALTA (Iptacopan) effective 2026-07-16. The updated label details are available on dailymed.nlm.nih.gov.